ICON selected by BARDA to conduct anthrax vaccine clinical trial

This clinical study will inform operational logistics and use of AV7909 should an anthrax emergency occur.

AGC begins study to expand its Bio-CDMO capability in Japan

Moderna creates new executive committee role for product launches

Juan Andres Appointed to President, Strategic Partnerships and Enterprise Expansion

Zentalis promotes Kevin Bunker to Chief Scientific Officer

Dr. Bunker will focus on leading Research and Development (R&D) in San Diego, advancing the preclinical pipeline and optimizing the Company’s Integrated Discovery Engine.

Hester planning capacity expansion for Goat Pox vaccine

Further, ICAR-IVRI have jointly developed a Lumpy Skin Disease vaccine and as soon as the technology is made available, Hester will acquire the same and manufacture and commercialize the Lumpy Skin disease Vaccine

Novartis unveils new focused strategy

Transformation to pure-play Innovative Medicines company nears completion

DAMAN enters ambitious European precision medicine healthcare project

Coordinated by the Medical University of Vienna, a consortium of 13 leading European organizations including university hospitals, research institutions and healthcare companies will conduct the 5-year project co-funded by Horizon Europe.

Parexel appoints Peyton Howell and Amy McKee

These moves are designed to strengthen the company’s medical and scientific focus and support its continued record growth through closer alignment of all aspects of strategy, sales, and delivery to delight customers

AstraZeneca likely to see substantial Evusheld uptake in Japan, says GlobalData

Japan’s Ministry of Health, Labour and Welfare (MHLW) has recently approved AstraZeneca's long-acting antibody combination “Evusheld” for the prevention ) and treatment of COVID-19.

Seagen, Astellas and Merck announce results of clinical trial investigating PADCEV with Keytruda for urothelial cancer

Results demonstrated a 64.5% confirmed objective response rate in patients treated with investigational combination of enfortumab vedotin and pembrolizumab